Trial · NCT03913130

Extension Study to Study PQ-110-001 (NCT03140969)

NCT03913130, Phase 1, Phase 2, Terminated, Laboratoires Thea; results first posted 2023-01-04

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Extension Study to Study PQ-110-001 (NCT03140969). Trials, record NCT03913130. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03913130

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Extension Study to Study PQ-110-001 (NCT03140969)
NCT number: NCT03913130
Status: Terminated
Phases: Phase 1, Phase 2
Enrollment: 9 participants, actual
Lead sponsor: Laboratoires Thea
Conditions: Leber Congenital Amaurosis 10, Blindness, Leber Congenital Amaurosis, Vision Disorders, Sensation Disorders, Neurologic Manifestations, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Retinal Disease
Interventions: QR-110
First posted: 2019-04-12
Last updated: 2024-10-15
Other registries' IDs: eudract:2018-003500-40
Results first posted: 2023-01-04

Source ClinicalTrials.gov

Registered outcomes14

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Frequency of Ocular AEs	24 months	Frequency of ocular adverse events (AEs)
Primary	Frequency of Non-ocular AEs	24 months	Frequency of non-ocular AEs
Secondary	Change in BCVA in First Treated Eye	24 months	Change in Best Corrected Visual Acuity (BCVA) in First Treated Eye
Secondary	Change in Mobility Course Score	24 months	Change in Mobility course score
Secondary	Change in Photoreceptor Outer Segment Layer Thickness	24 months	Change in photoreceptor outer segment layer thickness by Optical Coherence Tomography (OCT)
Secondary	Change in OCI	24 months	Change in Oculomotor Instability (OCI)
Secondary	Change in FST Blue	24 months	Change in Full-Field Stimulus Testing (FST) - blue stimuli
Secondary	Change in FST Red	24 months	Change in Full-Field Stimulus Testing (FST) - red stimuli
Secondary	Change in VFQ-25	24 months	Change in Visual Function Questionnaire-25 (VFQ-25) score (adult subjects)
Secondary	Change in CVAQ	24 months	Change in Cardiff Visual Ability Questionnaire for Children (CVAQC) score (pediatric subjects)

1 to 10 of 14Source ClinicalTrials.gov

See all 14 registered outcomes

Outcomes14

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Units	Measured as
PRIMARY	Frequency of Ocular AEs	24 months	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Frequency of Non-ocular AEs	24 months	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Change in BCVA in First Treated Eye	24 months	logMAR	MEAN
SECONDARY	Change in Mobility Course Score	24 months
SECONDARY	Change in Photoreceptor Outer Segment Layer Thickness	24 months
SECONDARY	Change in OCI	24 months
SECONDARY	Change in FST Blue	24 months
SECONDARY	Change in FST Red	24 months
SECONDARY	Change in VFQ-25	24 months
SECONDARY	Change in CVAQ	24 months

1 to 10 of 14Source ClinicalTrials.gov

See all 14 outcomes

Results by group5

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Frequency of Ocular AEs	Drug QR-110	7		Participants
Frequency of Non-ocular AEs	Drug QR-110	6		Participants
Change in BCVA in First Treated Eye	Drug QR-110	0.03	Standard Deviation 0.17	logMAR
Change in BCVA in Treated Contralateral Eye	Drug QR-110	-0.11	Standard Deviation 0.23	logMAR
Change in BCVA in Non-Treated Contralateral Eye	Drug QR-110	0.05	Standard Deviation 0.21	logMAR

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Drug QR-110	9
Overall Study	COMPLETED	Drug QR-110	8
Overall Study	NOT COMPLETED	Drug QR-110	1

Source ClinicalTrials.gov

Adverse events34

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Cataract	Eye disorders	Drug QR-110	1	9
other	Cataract cortical	Eye disorders	Drug QR-110	1	9
other	Cataract subcapsular	Eye disorders	Drug QR-110	2	9
other	Conjunctival haemorrhage	Eye disorders	Drug QR-110	2	9
other	Cystoid macular oedema	Eye disorders	Drug QR-110	1	9
other	Dry eye	Eye disorders	Drug QR-110	1	9
other	Eye pain	Eye disorders	Drug QR-110	1	9
other	Eye pruritus	Eye disorders	Drug QR-110	1	9
other	Lacrimation increased	Eye disorders	Drug QR-110	1	9
other	Lenticular opacities	Eye disorders	Drug QR-110	2	9

1 to 10 of 34Source ClinicalTrials.gov

See all 34 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Drug QR-110	0	9
Total, other adverse events	Drug QR-110	8	9
Total, serious adverse events	Drug QR-110	1	9

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03913130

GET https://conductscience.org/api/trials/v1/NCT03913130/events?page=2

API reference For AI assistants